Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers

CEO Tells Scrip Licensing Pact Is Its First, But Not Last

Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.

Cancer cell
LTX-315 is a first-in-class oncolytic peptide based immunotherapy • Source: Shutterstock

Norway’s Lytix Biopharmahas come out of stealth mode and landed its first commercial deal by licensing lead asset LTX-315 to US-based Verrica Pharmaceuticals, Inc., which will now develop and commercialize it for dermatologic oncology indications.

Lytix hopes successful development will allow the compound’s use in other oncology indications, its management told Scrip.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.